Skip to main content
. 2017 Dec 12;7:17465. doi: 10.1038/s41598-017-17302-4

Table 1.

Characteristics of the included CF patients (n = 114).

Variable N (%)
Sex Female 61 (52.6%)
Male 53 (47.4%)
Genotype F508del/F508del 48 (42.1%)
F508del/other 53 (46.5%)
G551D/other 15 (13.0%)
Other/other 13 (10.7%)
Age (yrs.) 0–5 17 (14.9%)
6–11 25 (21.9%)
12–17 14 (12.3%)
≥18 58 (50.9%)
Therapy Antibiotic therapy in the previous 3 months 84 (73.7%)
Pancreatic enzymes intake 107 (93.9%)
Proton pump inhibitors (PPI) 30 (36.3%)
Comorbidities Exocrine pancreatic insufficiency (EPI) 106 (93.0%)
Meconium ileus (MI) 9 (7.9%)
Distal intestinal obstruction syndrome (DIOS) 11 (9.6%)
Rectal prolapse 13 (11.4%)
CF liver disease (CFLD) 21 (18.4%)
Small bowel resection 9 (7.9%)
Serum Elevated ALT 60 (52.6%)
Elevated AST 25 (21.9%)
Elevated γ-GT 12 (10.5%)
Elevated AP 48 (42.1%)
Platelet counts reduced 5 (4.4%)

Elevated in regard to age and gender-related reference.

ALT: alanine aminotransferase; AST: aspartate aminotransferase; γ-GT: γ-glutamyl transpeptidase;

and AP: alkaline phosphatase.